Correlation between a gene polymorphism of tumor necrosis factor-α (G/A) and end-stage renal disease: A pilot study from north India

2006 ◽  
Vol 370 (1-2) ◽  
pp. 152-157 ◽  
Author(s):  
Parmeet Kaur Manchanda ◽  
Anant Kumar ◽  
Anupma Kaul ◽  
Rama Devi Mittal
Keyword(s):  
Pilot Study ◽  
Tumor Necrosis Factor ◽  
End Stage Renal Disease ◽  
Tumor Necrosis ◽  
Tumor Necrosis Factor Α ◽  
North India ◽  
Stage Renal Disease ◽  
Factor Α ◽  
End Stage ◽  
Necrosis Factor

Rheumatoid Hand Joint Synovitis: Gray-Scale and Power Doppler US Quantifications Following Anti–Tumor Necrosis Factor–α Treatment: Pilot Study

Radiology ◽  
2003 ◽  
Vol 229 (2) ◽  
pp. 562-569 ◽  
Author(s):  
Clio Ribbens ◽  
Béatrice André ◽  
Stefaan Marcelis ◽  
Olivier Kaye ◽  
Luc Mathy ◽  
...  
Keyword(s):  
Pilot Study ◽  
Tumor Necrosis Factor ◽  
Tumor Necrosis ◽  
Tumor Necrosis Factor Α ◽  
Power Doppler ◽  
Gray Scale ◽  
Doppler Us ◽  
Factor Α ◽  
Necrosis Factor

scholarly journals Augmentation of Cancer Cachexia Components With Targeted Acupuncture in Patients With Gastrointestinal Cancers: A Randomized Controlled Pilot Study

2019 ◽  
Vol 18 ◽  
pp. 153473541882326 ◽  
Author(s):  
Oliver Grundmann ◽  
Saunjoo L. Yoon ◽  
Joseph J. Williams ◽  
Lucio Gordan ◽  
Thomas J. George
Keyword(s):  
Pilot Study ◽  
Tumor Necrosis Factor ◽  
Tumor Necrosis ◽  
Tumor Necrosis Factor Α ◽  
Cancer Cachexia ◽  
Fat Free Mass ◽  
High Morbidity ◽  
Gi Cancer ◽  
Factor Α ◽  
Necrosis Factor

Introduction: Patients with gastrointestinal (GI) cancer-associated cachexia are at risk of high morbidity and mortality. This randomized single-blind pilot study compared the complementary use of targeted acupuncture (TA) with nontargeted acupuncture (NTA) for halting cachexia symptoms. Methods: GI cancer patients with cachexia undergoing chemotherapy were assigned to receive 8 weekly sessions of either TA (n = 15) or NTA (n = 15) following a specific acupuncture protocol. Bioelectrical impedance analysis and weight were measured weekly. Biological markers, including C-reactive protein, prealbumin, tumor necrosis factor-α, lactate dehydrogenase (LDH), leptin, and ghrelin blood levels were determined at specific intervals. Results: Prealbumin levels and fat-free mass were significantly higher in the NTA group at the end of the study, but remained stable in TA group. TA group had significantly lower (230 IU/L vs 288 IU/L, P = .04) LDH at the end of the study, but elevated tumor necrosis factor-α levels (13.15 pg/mL vs 9.24 pg/mL, P = .04). The absolute blood leptin and ghrelin levels decreased in the TA but remained stable in the NTA group. Both groups maintained weight, but the TA group trended toward weight gain during the last 2 weeks of the study. No adverse events related to acupuncture were reported. Conclusions: TA using predetermined, reproducible points may provide benefits to some patients with GI cancer cachexia by normalizing metabolic dysregulation. Elevated ghrelin levels are indicative of insulin resistance, which can lead to increased muscle loss represented by increased LDH activity in the NTA group. The pilot study provided completion rate and effect size for the primary outcome measures for a larger study. A longer treatment duration may be required to further refine these findings.

scholarly journals High Levels of Soluble Tumor Necrosis Factor Receptors 1 and 2 and Their Association with Mortality in Patients Undergoing Hemodialysis

2015 ◽  
Vol 5 (2) ◽  
pp. 89-95 ◽  
Author(s):  
Axel C. Carlsson ◽  
Juan-Jesús Carrero ◽  
Peter Stenvinkel ◽  
Matteo Bottai ◽  
Peter Barany ◽  
...  
Keyword(s):  
Tumor Necrosis Factor ◽  
End Stage Renal Disease ◽  
Inflammatory Markers ◽  
Regression Models ◽  
Tumor Necrosis ◽  
Tumor Necrosis Factor Receptors ◽  
Stage Renal Disease ◽  
End Stage ◽  
Necrosis Factor

Objective: Circulating soluble tumor necrosis factor receptors 1 and 2 (sTNFR1 and sTNFR2) are associated with chronic kidney disease (CKD) progression in patients with CKD or diabetes, and with higher mortality. However, data in patients with end-stage renal disease are scarce. Therefore, we analyzed serum levels of sTNFR1 and sTNFR2 and investigated their association with inflammatory markers and mortality in dialysis patients. Research Design and Methods: This was a longitudinal cohort study of 207 prevalent patients (median age 66 years, 56% men) undergoing hemodialysis in Stockholm, Sweden. Demographics, clinical characteristics, including comorbidities and laboratory data, were obtained at baseline, together with prospective follow-up for mortality. Results: The median sTNFR1 and sTNFR2 levels were 17,680 ng/l [95% confidence interval (CI) 17,023-18,337] and 24,450 ng/l (95% CI 23,721-25,179), respectively. During a follow-up of 31 months (interquartile range, 21-38), 77 patients died. There was no association between the levels of sTNFRs and mortality in Cox regression models, and no consistent trend towards higher or lower mortality was seen in Laplace regression models. sTNFR1 and sTNFR2 levels were highly associated with other inflammatory markers including interleukin-6, pentraxin 3 and TNF-α. Conclusions: Prevalent hemodialysis patients have several-fold higher levels of sTNFRs compared to previous studies in CKD stage 4 patients. As no consistent association between TNFR and mortality was observed, clinical implications of measuring these receptors to predict outcome end-stage renal disease patients provide limited results.

Sign in / Sign up

Export Citation Format

Share Document